Biomet Offers $280 Mil. For J&J’s DePuy Trauma Biz; Bid Facilitates Synthes Deal
This article was originally published in The Gray Sheet
J&J expects the divestiture to reduce regulatory barriers to its pending $21 billion Synthes acquisition.
You may also be interested in...
The company’s sports, extremities and trauma products generated 14% growth last quarter with the help of its JuggerKnot Soft Anchor sports medicine products.
J&J completes $19.7 billion Synthes purchase. ReVision Optics’ PresbyLens presbyopia trial update. Mindray gains controlling stake in Dragonbio. More news briefs.
Outstanding FDA questions pertain to follow-up data, user training and “post-market observance and those sorts of things,” CFO Dominic Caruso told investors during the firm’s first-quarter earnings call April 17.